| Action Summary | he changes to 12VAC5-90-80 include: removing Acquired immunodeficiency syndrome and Creutzfeldt-Jakob disease from the reportable disease list; adding infection or colonization with Candida auris and any carbapenemase-producing organism to the reportable disease list; adding the name of the reportable organism next to disease names on the reportable disease list and conditions reportable by laboratory directors so that the lists are more equally meaningful to both practicing clinicians and laboratorians; removing specific laboratory methods (e.g., test types) from the list of conditions reportable by laboratory directors and replacing with more general language requiring directors of laboratories to report based on any laboratory method if the method indicates the presence of a reportable organism; updating the list of conditions reportable by laboratory directors to reflect current laboratory technology and public health standards including reporting of all lead blood levels, reporting viral loads for persons who test positive for hepatitis C, reporting liver enzyme results for persons who test positive for hepatitis B, and reporting gram negative diplococci. Creutzfeldt-Jakob disease has been removed from the list of conditions reportable by laboratory directors and subsections E-I have been reordered so the titles are in alphabetic order. In addition, some language contained under 12VAC5-90-90, subsection B regarding the list of isolates or other specimens that must be submitted to the Division of Consolidated Laboratory Services has been moved to 12VAC5-90-80, as subsection D and has been updated. In addition, the isolate submission list also includes the names of reportable organisms next to disease names so that the isolate submission list is aligned with the reportable disease list and list of conditions reportable by laboratory directors and is more equally meaningful to practicing clinicians and laboratorians. |
| Chapters Affected | Only affects this chapter. |
| Executive Branch Review | This Action is exempt from Article 2 of the Administrative Process Act. The normal executive branch review process is not required. As such, it can be submitted directly for publication and is effective upon publication. Exempt Citation: 2.2-4002(A)(22) and 2.2-4006(A)(3) |
| RIS Project | Yes [005640] |
|
Is Federal action a driving factor in this regulatory change? If so, please provide a specific reference to the law, regulation
or court case.
N/A
|
|
| New Periodic Review | This action will not be used to conduct a new periodic review. |
| Stage ID | Stage Type | Status |
|---|---|---|
| 8375 | Final | Stage complete. This regulation became effective on 11/14/2018. |
| Name / Title: | Tim Powell / Acting Director, Division of Surveilance and Inves |
| Address: |
Virginia Department of Health 109 Governor Street Richmond, VA 23219 |
| Email Address: | tim.powell@vdh.virginia.gov |
| Phone: | (804)864-7760 FAX: ()- TDD: ()- |